InsiderTrades.com logo
J.P. Morgan’s DIRE Warning
From Behind the Markets   |   Ad
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
Click here to see why Wall Street is in PANIC mode >>>

LIPO Insider Trading

Insider Ownership Percentage: 39.58%
Insider Buying (Last 12 Months): $31,300.00
Insider Selling (Last 12 Months): $0.00

Lipella Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Lipella Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lipella Pharmaceuticals Share Price & Price History

Current Price: $0.42
Price Change: ▲ Price Increase of +0.02 (5.06%)
As of 07/26/2024 01:00 AM ET

This chart shows the closing price history over time for LIPO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Don't Pay a Dime for Marc Lichtenfeld's Top AI Picks
From The Oxford Club   |   Ad
Usually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...
Click here now to claim your FREE copy of Marc's AI playbook.

Lipella Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2024Jonathan H KaufmanInsiderBuy10,000$0.76$7,600.00898,849View SEC Filing Icon  
3/18/2024Jonathan H KaufmanInsiderBuy30,000$0.79$23,700.00863,849View SEC Filing Icon  
See Full Table
“Generational Bull Run” Incoming
From Unstoppable Prosperity   |   Ad
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
You can find out what they are by clicking here now.

SEC Filings (Institutional Ownership Changes) for Lipella Pharmaceuticals (NASDAQ:LIPO)

74.31% of Lipella Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Lipella Pharmaceuticals logo
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Read More on Lipella Pharmaceuticals

Today's Range

Now: $0.42
Low: $0.39
High: $0.43

50 Day Range

MA: $0.56
Low: $0.40
High: $0.76

52 Week Range

Now: $0.42
Low: $0.36
High: $2.71

Volume

51,214 shs

Average Volume

48,014 shs

Market Capitalization

$3.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Who are the company insiders with the largest holdings of Lipella Pharmaceuticals?

Lipella Pharmaceuticals' top insider shareholders include:
  1. Jonathan H Kaufman (Insider)
Learn More about top insider investors at Lipella Pharmaceuticals.
J.P. Morgan’s DIRE Warning
From Behind the Markets   |   Ad
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
Click here to see why Wall Street is in PANIC mode >>>